INSIGHTS ON ENTERPRISE SOLUTIONS

  • The Value Of Digital In Biopharma

    By working together across the biopharma industry, digital technology can be leveraged and data science can reengineer key elements of the drug manufacturing process to ease commercial scale-up.

  • Importance Of Chain Of Custody Documentation For Biologics

    Preventing patients from receiving “counterfeit, diverted, sub-potent, substandard, adulterated, misbranded, or expired drugs” is a critical element of the mission of the US Food and Drug Administration (FDA). Chain of custody for genetic and cell therapies differs and is more complex than for traditional pharmaceuticals, and the requirements for documentation vary as well.

  • Translating Biopharma Knowledge To Cell And Gene Therapies

    Streamlining, connecting, and automating workflows to shape the future of cellular treatment delivery has the potential to transform how we treat and potentially cure once life-threatening diseases.

  • Cell Therapy Manufacturing Under GMP - How And When To Get Started

    Emerging cellular therapies aim to manufacture cell populations for clinical indications, such as cancer, autoimmune, and cardiovascular diseases. As hospitals and translational facilities explore implementation of this technology they concurrently evaluate whether or not to manufacture the therapies onsite. Here is a guideline of how and when to get started.

  • Volume Reduction And Process Optimization With Cadence™ Inline Concentrator

    See how this solution not only provides additional capital savings but will also resolve potential manufacturing floor space limitations.

More Insights On Enterprise Solutions

ENTERPRISE SOLUTIONS MULTIMEDIA

  • Meet The API Drug Substance Team At Patheon’s Florence, SC Site

    Watch the video to meet Patheon’s (part of Thermo Fisher Scientific) API drug substance team and get an inside look at their Florence, SC facility.

  • Supporting The Transformation Of The Patient Experience With IASO

    IASO supports stakeholders who are responsible for bringing innovation to market in the form of combination products for oncology.  

  • Bioburden Control Concerns In Continuous Bioprocessing

    The industry is looking for answers about the implementation of continuous bioprocessing. Pall Biotech is here to help you to find them. Watch our video for quick insights into bioburden control strategies in continuous bioprocessing.

  • Standing Out In The Crowded Biopharma CDMO Market

    When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time. 

  • Singota Solutions—Focused on Faster

    This video introduces Singota Solutions, a CDMO focused on getting products to patients faster by being agile, accountable and transparent. A team of industry experts help virtual to large pharma clients reach preclinical and clinical milestones faster with shorter lead times and agile onsite operations. Services in formulation development, finishing and supply chain support Singota’s flagship aseptic filling operations. A gloveless robotic isolator provides highly repeatable and precise filling for high value drug products.

More Enterprise Solutions Multimedia

ENTERPRISE SOLUTIONS

  • AseptiQuik<sup>®</sup> G 1-1/2-inch Sanitary Connector
    AseptiQuik® G 1-1/2-inch Sanitary Connector

    The AseptiQuik G 1-1/2” Sanitary option expands CPC’s extensive termination offerings, which now include six termination sizes from 1/8” to 1” hose barbs, with 3/4” and 1-1/2” sanitary options.

  • AseptiQuik® G Connectors Datasheet

    Genderless AseptiQuik® G Connectors enable quick and easy sterile connections, even in non-sterile environments.

  • Sterile Fill/Finish
    Sterile Fill/Finish

    AbbVie’s new aseptic fill / finish vial line located in Sligo, northwest Ireland, is approximately 130 miles from Dublin. This state-of-the-art line supports lyophilization for potent and biologics along with liquid fill vials. Equipment installation is underway with production commencing H2 2020.

More Enterprise Solutions